Enveric Biosciences Inc (SLZA.SG)
- Business Wire
Enveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development Candidate
CAMBRIDGE, Mass., June 25, 2024--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced the Company is prioritizing the development of EB-003, its first-in-class approach to address difficult-to-treat mental health disorders. EB-003 and other neuroplastogens developed by Enveric are designed to prom
- Business Wire
Enveric Biosciences to Participate in BIO International Convention 2024
CAMBRIDGE, Mass., May 30, 2024--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that the Company will participate in the 2024 BIO International Convention taking place in San Diego, CA from June 3 – 6, 2024.
- Market Exclusive
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Key Takeaways; Cannabis Sector Ayr Wellness reported solid first quarter results. Cresco Labs reported stagnant sales but an optimistic outlook for 2024. Tilray announced a $250 million equity offering to fund U.S. asset acquisitions amid legalization optimism. Flora Growth is strategizing on cannabis reform to its reverse financial trend. Key Takeaways; Psychedelic Sector Enveric Biosciences […]
